非小细胞肺癌患者126例凝血3项指标改变的临床分析被引量：1

下载PDF

导出

摘要目的探讨非小细胞肺癌（NSCLC）患者凝血三项指标改变的临床意义。方法对126例NSCLC患者采用全自动血球分析仪,以电阻抗射频和细胞化学法测定血小板（PLT）;采用全自动血凝仪,分别以磁珠法和免疫比浊法测定纤维蛋白原（FIB）和D-二聚体（DD）。结果 126例患者中114例出现凝血功能异常,2例发生深静脉血栓;Ⅱ~Ⅳ期患者较Ⅰ期患者PLT、DD水平显著升高,转移组患者较无转移组患者FIB、DD水平显著升高,差异有统计学意义（P〈0.05）;鳞癌、腺癌两组相关指标比较的差异无统计学意义（P〉0.05）。结论 NSCLC患者FIB、DD水平与肿瘤分期、有无转移相关联。若能预防性抗凝治疗,预防血栓形成,对改善预后或有一定帮助。

作者蒋桂成崔同建俞训彬

机构地区福建医科大学省立临床医学院福建省立医院肿瘤内科福建省立医院病理科

出处《福建医药杂志》 CAS 2014年第3期88-91,共4页 Fujian Medical Journal

关键词非小细胞肺癌凝血功能抗凝

分类号 R734.2 [医药卫生—肿瘤] R446.1 [医药卫生—临床医学]

引文网络
相关文献

参考文献10

1李家增.止血异常与恶性肿瘤[J].血栓与止血学,2006,12(2):88-89. 被引量：29
2陆慰萱,黄金莹.肺血栓栓塞症第1讲肺血栓栓塞症的危险因素[J].中国临床医生杂志,2004,32(2):16-17. 被引量：3
3Nitori N,Ino Y,Nakanishi Y,et al.Prognostic signicance of tissue factor in pancreatic ductal adenocarcinoma[J].Clin Cancer Res,2005,11 (7):2531-2539. 被引量：1
4Donati M B,Lorenzet R.Coagulation factors and tumor cell biology; the role of tissue factor[J].Pathophsio haemost thromb,2003,33 (sumple1):22-25. 被引量：1
5Milanin-bMongiat J,Pouyssegur J,Pages G.Identification of two SpI phosphorylation sites for p42/p44 mitogen activated protein kinases:their implication in vascular endothelial growth factor gene transcription[J].Biol Chem,2002,277 (3):20631-20639. 被引量：1
6Karpatkin S.Does hypercoagulability awaken dormant tumor cells in the host?[J].Thromb Haehost,2004,2 (12):2103-2106. 被引量：1
7Arora P,Cuevas B D,Russo A,et al.Persistent transactiva tion of EGFR and ErbB2/HER2 by proteasactivated receptoP 1 promotes breast carcinoma cell invasion[J].Oncogene,2008,27 (32):4434-4445. 被引量：1
8姜正华,朱慕云,桑慧颖,吕元文,丁平,卞京文.肺癌患者凝血常规指标检测的临床意义[J].临床肺科杂志,2009,14(6):725-726. 被引量：24
9Altiay G,Ciftci A,Demir M,et al.High plasma D-dimer lev el is associated with decreased survival in patients with lung cancer[J].ClinOncol,2007,19 (7):494-498. 被引量：1
10陈云锋,邓梨平.凝血常规指导下晚期非小细胞性肺癌配合预防性抗凝治疗的临床观察[J].中南医学科学杂志,2012,40(5):493-495. 被引量：3

二级参考文献18

1阎飞,张定昌,李爱武,段力,涂志全,留红,钱严.血液流变性在肺癌发展过程中的变化规律[J].现代肿瘤医学,2004,12(4):277-278. 被引量：8
2白巧云,张金喜.肺癌患者凝血功能变化分析[J].浙江中西医结合杂志,2006,16(11):683-684. 被引量：9
3刘泽霖,刘敏涓,周立红,罗承锋,刘丽.抗栓治疗的循证指南[J].血栓与止血学,2007,13(1):45-48. 被引量：4
4Sallah S, Wan JY, Nguyan NP. Venous thrombosis in patients with solid tu-mors: Determination of frequency and characteristics. Thromb Haemost,2002,7:576 - 579. 被引量：1
5Kalweit GA, Feindt P, Micek M, et al. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies:comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res,2002,97(3) :105 -111. 被引量：1
6Pavey SJ, Hawson GA, Marsh NA. Impactof the fibfinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis,2001,12 ( 1 ) :51 - 58. 被引量：1
7Taguchi O, Gahazza EC, Yasui H, et al. Prognostic signification of plasma D-dimer levels in patients with lung cancer. Thorax, 1997, 52(6) :563 -565. 被引量：1
8Spyropoulos AC,Hussein M,Lin J. Rates of venous thromboembolism occurrence in medical patients among the insured population[J].Thrombosis and Haemostasis,2009,(05):951-957. 被引量：1
9Khorana AA,Francis CW,Culakova E. Frequency,risk factors,and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,(10):2339-2346.doi:10.1002/cncr.23062. 被引量：1
10Korte W. Cancer and thrombosis:an increasingly important association[J].Supportive Care in Cancer,2008,(03):223-228. 被引量：1